The pharmacokinetics of a B‐domain truncated recombinant factor VIII, turoctocog alfa (NovoEight®), in patients with hemophilia A

Publisher： John Wiley & Sons Inc

E-ISSN： 1538-7836|13|3|370-379

ISSN： 1538-7933

Source： JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Vol.13, Iss.3, 2015-03, pp. : 370-379

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Impact of severe haemophilia A on patients' health status: results from the guardian™ 1 clinical trial of turoctocog alfa (NovoEight®)

By  

HAEMOPHILIA, Vol. 21, Iss. 4, 2015-07 ,pp. : 451-457

John Wiley & Sons Inc

Access to resources Recommend Favorite

Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A

By  

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Vol. 13, Iss. 6, 2015-06 ,pp. : 967-977

John Wiley & Sons Inc

Access to resources Recommend Favorite

Long‐term patterns of safety and efficacy of bleeding prophylaxis with turoctocog alfa (NovoEight®) in previously treated patients with severe haemophilia A: interim results of the guardian™2 extension trial

By  

HAEMOPHILIA, Vol. 21, Iss. 5, 2015-09 ,pp. : e436-e439

John Wiley & Sons Inc

Access to resources Recommend Favorite

Long‐term patterns of safety and efficacy of bleeding prophylaxis with turoctocog alfa (NovoEight®) in previously treated patients with severe haemophilia A: interim results of the guardian™2 extension trial

By  

HAEMOPHILIA, Vol. 1351-8216, Iss. 5, 2015-09 ,pp. : e436-e439

John Wiley & Sons Inc

Access to resources Recommend Favorite

Pharmacokinetics, safety and efficacy of a recombinant factor IX product, trenonacog alfa in previously treated haemophilia B patients

By  

HAEMOPHILIA, Vol. 24, Iss. 1, 2018-01 ,pp. : 104-112

John Wiley & Sons Inc

Access to resources Recommend Favorite